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Abstract Lysophospholipids are liberated during venomous
action. In this study we demonstrated that lysophosphatidyl
choline (LPC) of various acyl chains enhances considerably the
activity of snake venom phosphodiesterase (PDE). Lysophos-
phatidic acid (LPA) and its cyclic form (cLPA), on the other
hand, were found to inhibit this enzyme in a non-competitive
(LPA) or competitive (cLPA) manner. Both of these activities
may contribute to the progression and subsidence of the
poisoning profile. PDE from cellular origin was not substantially
affected by any of the above lysophospholipids.
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1. Introduction
Phosphodiesterases (EC 3.1.4) are the enzymes which cata-
lyze the hydrolysis of phosphodiesters to phosphomonoesters.
They exist both intracellularly and extracellularly in a wide
variety of tissues and organisms [1^4]. Intracellular phospho-
diesterases (PDEs) play a role in signal transduction by regu-
lating the cellular concentrations of cyclic nucleotides [5]. Ex-
tracellular PDEs known as exonucleases, exist in venoms and
their route in envenomation is mostly by attacking nucleic
acids [6] through removal of mononucleotide units from the
polynucleotide chain in a stepwise fashion [7,8]. They also
possess the endonucleolytic activity towards single-stranded
DNA [9] and as such they have been used for sequencing
oligonucleotides and polynucleotides [10^13]. Many selective
inhibitors of each isoenzyme of intracellular PDEs have been
developed, which have many advantages in clinical use [14^
16]. However, for venom PDE only polyclonal anti-venom
antibodies and heparin have been reported as inhibitors [17^
20]. In this report we describe the e¡ect of various lysophos-
pholipids on the activity of snake venom PDE, as well as on
intracellular cAMP speci¢c PDE.
2. Materials and methods
2.1. Materials
Bis-p-nitrophenyl phosphate sodium salt (Bis-pNPP), 3-isobutyl-1-
methyl xanthine (IBMX), cAMP, DL-K-glycerophosphate disodium
salt hexahydrate, L-glycerophosphate disodium salt, and the snake
venom PDE were purchased from Sigma Chemicals (St. Louis,
MO). 1-Palmitoyl-2-hydroxy-sn-glycero-3-phosphate (lysophosphati-
dic acid, LPA) monosodium salt, 1-oleolyl-2-hydroxy-sn-glycero-3-
phosphocholine, 1-palmitoyl-2-hydroxy-sn-glycero-3-phosphocholine
and 1-caproyl-2-hydroxy-sn-glycero-3-phosphocholine were obtained
from Avanti Polar Lipids (Albaster, AL). Tritium labelled cAMP
was procured from American Radiolabelled Chemicals, Inc. (St.
Louis, MO) and Lumax was purchased from Lumac-LSC (Gronin-
gen, The Netherlands). Cyclic palmitoyl lysophosphatidic acid (cLPA)
was synthesized by dehydration of the acid form of LPA with dicy-
clohexylcarbodiimide in dimethylsulfoxide. The obtained product was
analytically pure. A full account on the synthesis of cLPA will be
published elsewhere. All other chemicals and solvents used were of
analytical grade.
2.2. Cells and cell lysates
NIH 3T3 cells were grown in tissue culture at 37‡C under 5% CO2
atmosphere in the presence of 1640 Eagle medium and 10% bovine
calf serum. Cells were washed thoroughly with phosphate bu¡ered
saline (PBS) and then lysed by freeze-thawing.
2.3. Assay of snake venom phosphodiesterase
The activity of snake venom PDE was assayed in 1 ml of 50 mM
Tris-HCl bu¡er, pH 8.4 containing 5 mM bis-pNPP and snake venom
PDE (10 Wg). The reaction was arrested by the addition of 50 Wl of 0.5
N NaOH, at the end of 1 h incubation at 37‡C. The p-nitrophenol
liberated was monitored at 405 nm in a UV double beam spectropho-
tometer.
2.4. Assay of cyclic AMP degradation
cAMP degradation activity of the cell lysate was monitored by
radiolabelled 3H-cAMP as described [21]. 3H-cAMP (0.5 million
counts) was incubated with snake venom PDE (10 Wg) and cell lysate
(50 Wg protein) for 1 h at 37‡C in a reaction mixture of ¢nal volume
200 Wl containing 50 mM Tris-HCl bu¡er, pH 7.4, and 0.1 mM
cAMP. The reaction was stopped by adding 0.1 ml of a solution
containing 2% SDS, 1 mM cAMP and 45 mM ATP, followed by
boiling for 5 min. Then 0.9 ml of double distilled water was added
and mixed well. The reaction mixture was then passed through a
Dowex AG50 WX4 and neutral chromatographic alumina WN-3 col-
umns (0.4U15 cm) respectively. Finally, the radiolabelled 3H-cAMP
was eluted from the alumina column by using 4.0 ml of imidazole-HCl
bu¡er (0.1 M, pH 7.5) and 4.0 ml of scintillation £uid was added and
mixed well. The radioactivity was measured in a Beckman-LS5000TD
model L-counter. At the same time control reaction also was run as
mentioned above but without the enzyme. The enzyme activity was
presented in terms of percentage of 3H-cAMP degradation with re-
spect to control.
3. Results
3.1. Activation of snake venom PDE by lysophospholipids
Phospholipase A2 (PLA2) is a major component in snake
venom. It acts predominantly on phosphatidyl choline (PC) to
liberate lysoPC (LPC) which in turn disintegrate cell mem-
branes. Our preliminary tests indicated that LPC of various
acyl chains can activate snake venom PDE in a dose depend-
ent manner. In the presence of 50 WM of LPC compounds the
activation approached its maximal level and was in the range
of 75^85%. LPC can be further degraded to lysophosphatidic
acid (LPA) [22,23] by lysophospholipase D in the rat [24] and
human [25] sera. The cyclic form of LPA (cLPA) [26,27] ap-
pears as an intermediate in this reaction [25^27]. The e¡ects
on snake venom PDE of di¡erent LPCs, as well as LPA and
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cLPA, are summarized in Table 1. All the LPC compounds
were found to increase the enzyme activity. Among them 1-
oleolyl-2-hydroxy-sn-glycero-3-phosphocholine showed high-
est activation while 1-caproyl-2-hydroxy-sn-glycero-3-phos-
phocholine exhibited the lowest activation.
3.2. Inhibition of snake venom PDE by cLPA and LPA
In contrast to LPC, at 50 WM cLPA imposed almost com-
plete inhibition of the enzyme activity while its open form
LPA showed approximately 50% inhibition at 50 WM. Fig. 1
presents the e¡ect of di¡erent concentrations of cLPA and
LPA on venom PDE. As shown, the e¡ect of LPA levelled
o¡ at approximately 50% inhibition while the inhibition by
cLPA increased steadily and approached complete inhibition.
It could be therefore assumed that the inhibitory e¡ect of
LPA is non-competitive while that of cLPA could be a com-
petitive one. The inhibitory action of cLPA on the venom
PDE activity was therefore analyzed according to the classical
Michaelis-Menten mechanism. Fig. 2 shows the e¡ect of 50
WM cLPA on PDE activity in 1/V vs. 1/S plot. As shown, the
two lines intersect on the 1/V axis (at 1/Vmax), which indicates
that the inhibition is competitive. The inhibitory e¡ects of
LPA and cLPA on the snake venom PDE prompted us to
test a series of related compounds at the 50^100 WM range.
This series included K-glycerophosphate, L-glycerophosphate,
1,2-cyclic glycerophosphate, palmitic acid, monopalmitoyl
glycerol and phosphatidic acid. None of these compounds
displayed any signi¢cant inhibitory action on this enzyme
(data not shown), strongly suggesting that the observed e¡ects
of LPA and cLPA are speci¢c.
3.3. E¡ect of snake venom PDE on cAMP degradation
Snake venom PDE did not degrade cAMP (data not
shown). The di¡erence in substrate speci¢city between the
venom and the intracellular PDEs was further con¢rmed by
the e¡ect of IBMX, and theophylline, the conventional inhib-
itors of cAMP-PDEs [28,29] on snake venom PDE. None of
these inhibitors displayed inhibition activity on the venom
PDE. Furthermore, the cell lysate PDE did not act on bis-
pNPP.
3.4. E¡ect of phospholipids on cAMP speci¢c
phosphodiesterase from NIH 3T3 cells
The e¡ect of the lysophospholipids tested with venom PDE
(see above) was further checked on cellular PDE using NIH
3T3 cells. As expected, the cell lysate contained PDE speci¢c
to cAMP, as shown in Fig. 3. IBMX, a known inhibitor of
cAMP PDE [22] was used as a reference (see Fig. 3). Of all the
lysophospholipids which e¡ected the venom PDE activity,
only LPA exhibited inhibition activity but only at concentra-
tion above 1 mM (see Fig. 3). The inhibition of cAMP deg-
radation by LPA was reached within a few minutes (data not
shown) and it remained thereafter unchanged as expected
from a simple e¡ect of ¢nding.
4. Discussion
The results presented in this paper clearly indicate that ven-
om PDE is markedly di¡erent from cellular PDE with respect
to substrates and inhibitors. The snake venom contains the
enzymes phospholipase A2 (PLA2) and PDE as major venom-
ous components [30,31]. The prime substrate for PLA2 is
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Fig. 1. Inhibition of snake venom PDE by increasing concentration
of cLPA (circles) and LPA (diamonds).
Fig. 2. Lineweaver-Burk plot (reciprocal of enzyme V vs. reciprocal
of substrate concentration S) of snake venom PDE activity in the
absence (squares) and presence (circles) of 50 WM palmitoyl cLPA.
Fig. 3. Level of 3H-cAMP after incubation with NIH 3T3 cell lysate
in the absence and presence of IBMX, LPA and cLPA. The pre-
sented values are means of triplicates. For experimental details see
text.
R. Mamillapalli et al./FEBS Letters 436 (1998) 256^258 257
phosphatidyl choline (PC) which upon cleavage is converted
to lysoPC. In this study, we demonstrated that lysoPC of
various acyl chains acts as an activator of snake venom
PDE (see Table 1). This ¢nding raises the possibility that
upon venom inception PLA2 and PDE act in tandem, i.e.
the liberate lysoPC, which causes cell lysis acts further to
activate the PDE in its deleterious DNA and RNA degrada-
tion. Phospholipase D, which is present in various tissues [32]
including the plasma [24,25], can in principle convert lysoPC
to the cLPA cyclic form of lysophosphatidic acid [26]. We
have recently observed such an activity in human plasma
[25]. This unique phospholipid [26] was shown here to inhibit
the activity of snake venom phosphodiesterase in a classical
competitive fashion (see Fig. 2). In this respect it might be
proposed that the cleavage of lysoPC by phospholipase D is
one of the mechanisms responsible for subsiding the venom-
ous action. The open form of cLPA, i.e. LPA which is also
formed in this enzymatic reaction has also an inhibitory e¡ect
on the venom PDE in a non-competitive nature which can
only attenuate the activity of this enzyme by approximately
50% (see Table 1 and Fig. 1). Unlike the case of the venom
enzyme, LPA showed inhibitory action on this enzyme only at
concentrations in the millimolar range (see Fig. 3), which are
much higher than those expected to be found in biological
systems. Furthermore, the various LPC compounds had no
e¡ect on the cell lysate PDE.
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Table 1
E¡ect of lysophospholipids on snake venom phosphodiesterase activity
Lysophospholipid (50 WM) Activity (%)
1-oleolyl-2-hydroxy-sn-glycerol-3-phosphocholine 164
1-palmitoyl-2-hydroxy-sn-glycero-3-phosphocholine 162
1-caproyl-2-hydroxy-sn-glycero-3-phosphocholine 142
1-palmitoyl-2-hydroxy-sn-glycero-3-phosphate 50
1-palmitoyl 2,3-cyclic-sn-glycerophosphate 5
Lysophospholipids (50 Wl of 1 mM) were added to the enzyme reaction mixture (950 Wl) prior to venom PDE enzyme (10 Wg/ml) and incubated for
1 h at 37‡C. The enzyme activity was determined as described in Section 2.3 and in the absence of lysophospholipid was taken as 100% activity.
Data represent the means of three separate enzyme assays. For each of the presented values, S.D.6 þ 10%.
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